Controls extrapyramidal disorders (except tardive dyskinesia - see PRECAUTIONS ) due to…. ANDA 209442, held by Hikma Pharmaceuticals. Benztropine Mesylate.
As of Nov 22, 2026, ANDA 209442 (Benztropine Mesylate), held by Hikma Pharmaceuticals, was first approved by FDA on Oct 14, 2021, with 0 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE For use as an adjunct in the therapy of all forms of parkinsonism (see DOSAGE AND ADMINISTRATION ). Useful also in the control of extrapyramidal disorders (except tardive dyskinesia - see PRECAUTIONS ) due to neuroleptic drugs (e.g., phenothiazines).
| Date | Submission | Status | Documents |
|---|---|---|---|
| Oct 14, 2021 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Benztropine Mesylate1MG/ML · injectable;injection | Benztropine Mesylate | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters